The study is expected to enroll about 45 adult participants with a C9orf72 mutation, the clinical-stage drugmaker said. The primary endpoint is safety, tolerability, pharmacokinetics and pharmacodynamics of AL001.
Shares of Alector are up 7% in late morning trading, while shares of GlaxoSmithKline are down more than 1%.
Price: 23.36, Change: +1.70, Percent Change: +7.88
|Street Color: Global Calendar For Week Ending May 20|
|Ryder System Receives $4.4 Billion Cash Buyout Propo...|
|Payoneer Shares Rally After Q1 Beats Expectations, 2...|
|Market Chatter: Alibaba Group's Venture in Russia Re...|
|Research Alert: CFRA Raises View On Paycom Software ...|